3.010CHF-4.14%Mkt Cap: 112.91M CHFP/E: —Last update: 2026-05-13
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP03…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)12.86
PEG—
P/B1.38
P/S—
EV/EBITDA-0.70
EV/Revenue—
EPS (TTM)-1.55
EPS (Forward)0.23
Cash Flow & Leverage
FCF Yield-22.13%
FCF Margin—
Operating CF-51.26M CHF
CapEx (TTM)714.00K CHF
Net Debt/EBITDA1.45
Net Debt-75.42M CHF
Technical
SMA 503.361 (-10.4%)
SMA 2003.222 (-6.6%)
Beta—
S&P 52W Chg24.23%
Avg Vol (30d)30.05K
Avg Vol (10d)27.31K
Technical Indicators
RSI (14)36.8
MACD-0.0610
MACD Signal-0.0374
MACD Hist.-0.0235
BB Upper3.520 CHF
BB Middle3.295 CHF
BB Lower3.069 CHF
BB Width13.69%
ATR (14)0.2094 CHF
Vol Ratio (20d)2.86x
52W Range
2.66027% of range3.960
52W High3.960 CHF
52W Low2.660 CHF
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE-76.74%
ROA-60.38%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity0.05
Current Ratio9.43
Quick Ratio9.21
Book Value/Sh2.147 CHF
Cash/Share2.097 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.37.51M
Float19.89M
Insiders8.47%
Institutions43.82%
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)9.000 CHF
Target Range3.000 CHF – 15.00 CHF
# Analysts2
Company
Market Cap112.91M CHF
Enterprise Value36.11M CHF
Revenue (TTM)—
Gross Profit-39.14M CHF
Net Income (TTM)-61.65M CHF
Revenue/Share—
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees134
Last Price3.010 CHF
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0256379097